Medicare to Lower Prices on 15 Key Prescription Drugs, Including Ozempic and Cancer Treatments
Table of Contents
Medicare will lower prescription drug costs for millions of Americans, starting January 2027, following a new round of federal price negotiations authorized by the Inflation Reduction Act. The move is projected to save taxpayers billions of dollars and provide significant relief to seniors facing high medical expenses.
Which Medications Will See Price Reductions?
The Centers for Medicare & Medicaid Services (CMS) announced that the price cuts will apply to 15 widely used drugs across several major therapeutic areas. These include:
- GLP-1 medications: Ozempic and Wegovy, commonly used for both diabetes and weight loss.
- Cancer treatments: Xtandi, Pomalyst, and Ibrance.
- Asthma and respiratory drugs: Trelegy Ellipta and Breo Ellipta.
- Diabetes medicines: Tradjenta, Janumet, and Janumet XR.
- Neurological and movement-disorder drugs: Austedo and Austedo XR.
- Gastrointestinal treatments: Linzess and Xifaxan.
- Other specialty medicines: Otezla and Calquence.
According to CMS data, over 5 million Medicare patients utilized these medications in 2024.
How the Price Cuts Came About
These reductions represent the second phase of price negotiations enabled by the Inflation Reduction Act, which for the first time allows Medicare to directly negotiate drug prices with pharmaceutical companies. Last year, Medicare secured lower prices for an initial 10 drugs, with those savings scheduled to take effect in 2026. This latest announcement significantly expands the program’s reach.
CMS estimates the new pricing structure will generate approximately $12 billion in government savings, alleviating pressure on federal health spending. However, it’s important to note that these reduced prices will not be implemented until January 2027.
A Response to Rising Healthcare Costs
The announcement arrives amidst escalating demand for weight-loss drugs – particularly GLP-1 medications – and a broader trend of increasing pharmaceutical expenditures. An estimated 16 million Americans are currently taking GLP-1 medications, with a substantial portion using them for weight management rather than diabetes treatment.
“The cuts come at a critical time, as many Americans struggle to afford the medications they need,” a senior official stated.
The program is expected to remain a point of contention, with pharmaceutical companies expressing concerns that price negotiations will stifle innovation. Conversely, health advocates maintain that access to life-saving medications must be affordable for older Americans. One analyst noted that the long-term impact on pharmaceutical research and development remains to be seen.
The debate underscores the complex challenges of balancing pharmaceutical innovation with the need for accessible and affordable healthcare.
